Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
San Gabriel Valley Index
San Gabriel Valley
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Pliant Therapeutics Inc
(NQ:
PLRX
)
12.55
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Pliant Therapeutics Inc
< Previous
1
2
3
4
5
6
Next >
PLRX Stock Earnings: Pliant Therapeutics Misses EPS for Q2 2024
August 07, 2024
PLRX stock results show that Pliant Therapeutics missed analyst estimates for earnings per share the second quarter of 2024.
Via
InvestorPlace
Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results
August 07, 2024
From
Pliant Therapeutics, Inc.
Via
GlobeNewswire
Pliant Therapeutics to Participate in the Canaccord Genuity 44th Annual Growth Conference
August 06, 2024
From
Pliant Therapeutics, Inc.
Via
GlobeNewswire
Pliant Therapeutics Announces Positive Long-Term Data from the INTEGRIS-PSC Phase 2a Trial Demonstrating Bexotegrast was Well Tolerated at 320 mg with Continued Antifibrotic and Anti-Cholestatic Activity Displayed Across Multiple Measures
July 15, 2024
From
Pliant Therapeutics, Inc.
Via
GlobeNewswire
These Analysts Revise Their Forecasts On Pliant Therapeutics Following Q1 Earnings
May 07, 2024
Via
Benzinga
The Latest Analyst Ratings for Pliant Therapeutics
November 10, 2023
Via
Benzinga
7 Biotech Stocks to Buy on the Dip: June 2024
June 24, 2024
With health being a top priority over wealth generation, these biotech stocks to buy on the dip enjoy a sound framework for speculation.
Via
InvestorPlace
Pliant Therapeutics Announces Appointment of Steve Krognes to Board of Directors
June 13, 2024
From
Pliant Therapeutics, Inc.
Via
GlobeNewswire
Pliant Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
June 12, 2024
From
Pliant Therapeutics, Inc.
Via
GlobeNewswire
Pliant Therapeutics Presents Data from its Bexotegrast Program at the European Association for the Study of the Liver (EASL) International Liver Congress™
June 06, 2024
From
Pliant Therapeutics, Inc.
Via
GlobeNewswire
Pliant Therapeutics Presents Data from its Bexotegrast Program at the American Thoracic Society International Conference
May 21, 2024
From
Pliant Therapeutics, Inc.
Via
GlobeNewswire
Pliant Therapeutics' Drug Trial Shows Promise In Reversing Lung Fibrosis In Patients
May 14, 2024
Phase 2a trial results of Pliant Therapeutics' bexotegrast (PLN-74809) for idiopathic pulmonary fibrosis. Reduced lung collagen, improved FVC, and cough severity, signaling potential fibrosis...
Via
Benzinga
Pliant Therapeutics Announces Positive Topline Data from a Phase 2a Collagen PET Imaging Clinical Trial of Bexotegrast in Patients with Idiopathic Pulmonary Fibrosis
May 14, 2024
From
Pliant Therapeutics, Inc.
Via
GlobeNewswire
Pliant Therapeutics Announces Upcoming Presentations at the European Association for the Study of the Liver International Liver Congress™
May 07, 2024
From
Pliant Therapeutics, Inc.
Via
GlobeNewswire
PLRX Stock Earnings: Pliant Therapeutics Misses EPS for Q1 2024
May 06, 2024
PLRX stock results show that Pliant Therapeutics missed analyst estimates for earnings per share the first quarter of 2024.
Via
InvestorPlace
Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
May 06, 2024
From
Pliant Therapeutics, Inc.
Via
GlobeNewswire
Pliant Therapeutics to Participate in Upcoming Investor Events
May 01, 2024
From
Pliant Therapeutics, Inc.
Via
GlobeNewswire
Pliant Therapeutics to Participate in Upcoming Investor Events
April 02, 2024
From
Pliant Therapeutics, Inc.
Via
GlobeNewswire
Pliant Therapeutics Announces Upcoming Presentations at the 2024 American Thoracic Society International Conference
March 27, 2024
From
Pliant Therapeutics, Inc.
Via
GlobeNewswire
Pliant Therapeutics Announces Accelerated Bexotegrast Development Plan for the Treatment of Idiopathic Pulmonary Fibrosis
March 12, 2024
From
Pliant Therapeutics, Inc.
Via
GlobeNewswire
Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2023 Financial Results
February 27, 2024
From
Pliant Therapeutics, Inc.
Via
GlobeNewswire
Pliant Therapeutics to Participate in Upcoming Investor Conferences
February 26, 2024
From
Pliant Therapeutics, Inc.
Via
GlobeNewswire
Pliant Therapeutics to Participate in Upcoming Investor Events
February 07, 2024
From
Pliant Therapeutics, Inc.
Via
GlobeNewswire
Why Air Products and Chemicals Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Monday's Mid-Day Session
February 05, 2024
Shares of Air Products and Chemicals, Inc. (NYSE: APD) fell sharply during Monday’s session after the company reported worse-than-expected first-quarter financial results and lowered FY24 adjusted EPS...
Via
Benzinga
Why Is Liver Disease-Focused Pliant Therapeutics Stock Trading Lower Today?
February 05, 2024
Pliant Therapeutics reports 12-week interim data for bexotegrast in INTEGRIS-PSC Phase 2a trial. 320 mg group met primary and secondary endpoints, showing well-tolerance and reduction in liver...
Via
Benzinga
HC Wainwright & Co. Maintains Buy Rating for Pliant Therapeutics: Here's What You Need To Know
February 05, 2024
Via
Benzinga
Pliant Therapeutics Announces Positive Safety and Exploratory Efficacy Data from the INTEGRIS-PSC Phase 2a Trial of Bexotegrast 320 mg in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis
February 04, 2024
From
Pliant Therapeutics, Inc.
Via
GlobeNewswire
Pliant Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
January 03, 2024
From
Pliant Therapeutics, Inc.
Via
GlobeNewswire
Pliant Therapeutics Presentations at The Liver Meeting® 2023 Highlight Bexotegrast, an Inhibitor of αvß6 and αvß1 Integrins, in Primary Sclerosing Cholangitis
November 13, 2023
INTEGRIS-PSC interim results highlighted in an oral late-breaker presentation
From
Pliant Therapeutics, Inc.
Via
GlobeNewswire
Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results
November 09, 2023
From
Pliant Therapeutics, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.